Pages that link to "Q44023106"
Jump to navigation
Jump to search
The following pages link to A crossover, add-on trial of talampanel in patients with refractory partial seizures (Q44023106):
Displaying 41 items.
- Talampanel as add-on therapy for the treatment of refractory partial epilepsy (Q24202725) (← links)
- Revisiting AMPA receptors as an antiepileptic drug target (Q24611163) (← links)
- Diverse mechanisms of antiepileptic drugs in the development pipeline (Q24675330) (← links)
- Molecular targets for antiepileptic drug development (Q24683346) (← links)
- Perampanel in the management of partial-onset seizures: a review of safety, efficacy, and patient acceptability (Q26796447) (← links)
- Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions (Q28245021) (← links)
- Glutamate receptor ion channels: structure, regulation, and function (Q28290774) (← links)
- Early alterations of AMPA receptors mediate synaptic potentiation induced by neonatal seizures (Q30487499) (← links)
- Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas (Q33759231) (← links)
- Talampanel (Q34573705) (← links)
- Neuroprotective and anticonvulsant effects of EGIS-8332, a non-competitive AMPA receptor antagonist, in a range of animal models (Q34580749) (← links)
- Emerging drugs for epilepsy (Q34688725) (← links)
- Talampanel suppresses the acute and chronic effects of seizures in a rodent neonatal seizure model (Q34946029) (← links)
- Novel anticonvulsant medications in development (Q34974862) (← links)
- A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis (Q35015986) (← links)
- The AMPA receptor antagonist perampanel in the adjunctive treatment of partial-onset seizures: clinical trial evidence and experience (Q35537344) (← links)
- Treatment of early and late kainic acid-induced status epilepticus with the noncompetitive AMPA receptor antagonist GYKI 52466 (Q35950960) (← links)
- Ionotropic and metabotropic glutamate receptor structure and pharmacology (Q36054635) (← links)
- Protection from fatal viral encephalomyelitis: AMPA receptor antagonists have a direct effect on the inflammatory response to infection (Q36491096) (← links)
- Antiepileptic drugs in development (Q36655604) (← links)
- Development of new antiepileptic drugs: challenges, incentives, and recent advances (Q36913503) (← links)
- Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial (Q37325097) (← links)
- New and investigational antiepileptic drugs (Q37638688) (← links)
- New AMPA antagonists in epilepsy. (Q38025721) (← links)
- Perampanel, a novel, non-competitive, selective AMPA receptor antagonist as adjunctive therapy for treatment-resistant partial-onset seizures (Q38069246) (← links)
- BGG492 (selurampanel), an AMPA/kainate receptor antagonist drug for epilepsy (Q38154633) (← links)
- The discovery and development of perampanel for the treatment of epilepsy (Q38190084) (← links)
- Experimental trials in amyotrophic lateral sclerosis: a review of recently completed, ongoing and planned trials using existing and novel drugs (Q38223292) (← links)
- Drug-induced cerebellar ataxia: a systematic review (Q38267726) (← links)
- Mechanism of inhibition of the GluA2 AMPA receptor channel opening by talampanel and its enantiomer: the stereochemistry of the 4-methyl group on the diazepine ring of 2,3-benzodiazepine derivatives (Q39931409) (← links)
- Profile of perampanel and its potential in the treatment of partial onset seizures (Q41015834) (← links)
- Radiosynthesis and preliminary PET evaluation of (18)F-labeled 2-(1-(3-fluorophenyl)-2-oxo-5-(pyrimidin-2-yl)-1,2-dihydropyridin-3-yl)benzonitrile for imaging AMPA receptors (Q41634484) (← links)
- Perampanel: a selective AMPA antagonist for treating seizures (Q41873465) (← links)
- Perampanel: A novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy (Q44721490) (← links)
- Unified pharmacogenetics-based parent-metabolite pharmacokinetic model incorporating acetylation polymorphism for talampanel in humans (Q46829368) (← links)
- Anti-ictogenic and antiepileptogenic properties of perampanel in mature and immature rats. (Q47888996) (← links)
- Tolerability and safety of perampanel: two randomized dose-escalation studies. (Q55054824) (← links)
- Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: Results of randomized global phase III study 305 (Q56960260) (← links)
- Synthesis, Chiral Resolution and Pharmacological Evaluation of a 2,3-Benzodiazepine-Derived Noncompetitive AMPA Receptor Antagonist (Q58862988) (← links)
- Synthesis, pharmacology and preclinical evaluation of C-labeled 1,3-dihydro-2H-benzo[d]imidazole-2-ones for imaging γ8-dependent transmembrane AMPA receptor regulatory protein (Q62039080) (← links)
- Radiosynthesis and preliminary evaluation of 11C-labeled 4-cyclopropyl-7-(3-methoxyphenoxy)-3,4-dihydro-2H-benzo[e] [1,2,4] thiadiazine 1,1-dioxide for PET imaging AMPA receptors (Q90175645) (← links)